The global Smart Insulin Pens Market is experiencing substantial growth, driven by the increasing prevalence of diabetes, ...
Market OverviewThe Global Smart Insulin Pens Market was valued USD 102.86 Million in 2022 and is anticipated to reach a value ...
As many as 50 children aged below 18 were screened at the special camp for Type 1 Diabetes at the District Early Intervention Centre (DEIC) on Thursday ...
California made a big bet on producing its own insulin. There’s no ‘date certain’ for delivery
California dedicated $100 to manufacturing insulin for diabetic residents. That effort is taking longer than Gov. Gavin ...
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar ... Both a 3-mL ...
Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.
And because pharmacies can’t break up boxes containing five insulin pens, patients can also be charged double depending on the amount prescribed. Lipska, a researcher at the Center for Outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback